Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma hosted a virtual R&D Day on March 5, 2021, featuring a live Q&A session available for analysts and investors.
Prerecorded materials detailing Zealand's development pipeline and five-year R&D strategy are accessible on its website. The virtual event includes insights from various executives about the company's ambitious plans for 2025 and its peptide-based medicines for metabolic and gastrointestinal diseases. Zealand Pharma aims to enhance its market position backed by collaborations with major pharmaceutical companies.
Zealand Pharma announced a conference call on March 11, 2021, at 4 PM CET (10 AM ET) to present its Full Year Results for 2020. Senior executives, including President Emmanuel Dulac and CFO Matt Dallas, will discuss the results followed by a Q&A session. Participants can join via multiple dial-in numbers provided for various countries, and a live audio webcast will be available on Zealand's Investor website. A recording and transcript will follow.
Zealand Pharma A/S (Nasdaq: ZEAL) announced its participation in two upcoming investor conferences in March 2021. The Credit Suisse 2021 London Global Healthcare Conference will take place on March 2, while the Jefferies Pan-European Mid-Cap Virtual Conference is scheduled for March 30. Zealand Pharma is focused on innovative peptide-based medicines and has advanced multiple drug candidates into clinical development, including V-Go, an insulin delivery option for diabetes patients.
Zealand Pharma A/S (Nasdaq: ZEAL) announced its participation in the SVB Leerink 9th Annual Global Healthcare Conference on February 24, 2021. Members of Zealand's senior management will present virtually at 8:00 a.m. ET. A live webcast can be accessed on the company’s website, with a replay available after the event. Zealand focuses on developing peptide-based medicines and is advancing multiple drug candidates, including one under review for regulatory approval in the U.S.
Zealand Pharma A/S (Nasdaq: ZEAL) announced the disclosure of transactions conducted by managerial personnel and their associates concerning the company's shares. This announcement is part of compliance with regulatory requirements and does not indicate any significant changes in management strategy or financial performance. Zealand Pharma, focused on innovative peptide-based medications, boasts a robust pipeline with over ten candidates in clinical development, two of which are already on the market. For further details, consult the attached documents.
Zealand Pharma will host a virtual R&D Day on March 5, 2021, showcasing progress in its R&D pipeline and its five-year strategy. The event will include a pre-recorded session, accessible on March 4, followed by a live Q&A session at 4:00 p.m. CET (10:00 a.m. ET). This aims to provide analysts and investors with insights into Zealand's innovative peptide-based medicines, including candidates in late-stage development and ongoing regulatory reviews in the U.S.
For more information, visit the Events & Presentations page on Zealand's website.
Zealand Pharma has completed a capital increase of DKK 3,600,841 through the issuance of 3,600,841 new ordinary shares. Following this increase, the company's total share capital now stands at DKK 43,400,547, totaling 43,400,547 shares. The new shares will be admitted to trading on Nasdaq Copenhagen with their permanent ISIN code, expected to merge with the temporary code by February 3, 2021. The offering was managed by Goldman Sachs International, Jefferies GmbH, and Danske Bank A/S.
Zealand Pharma A/S (NASDAQ: ZEAL) announced changes to its share capital, effective September 30, 2020. The total number of shares has increased to 39,778,961, with corresponding voting rights also at 39,778,961. This increase is attributed to the exercise of employee warrants as previously disclosed in Company announcement No. 48/2020. Zealand focuses on innovative peptide-based medicines and has multiple candidates in late-stage development.
Zealand Pharma has announced amendments to its Articles of Association following the granting of employee warrants. The company aims to attract and retain top talent through this incentive scheme, aligning interests of management, employees, and shareholders. The related share capital increase has been officially registered with the Danish Business Authority. Zealand Pharma, based in Copenhagen, has a focus on innovative peptide-based medicines, with several drug candidates in clinical development and collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals.
